+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028

  • ID: 4668466
  • Drug Pipelines
  • May 2022
  • Region: Global
  • 400 Pages
  • Kuick Research

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma

Chimeric antigen receptor (CAR) T cell therapy is a novel immunotherapeutic approach that is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor). This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.  

The introduction of CAR T cell therapies has shown high adoption rates in a short span of time has propelled further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of the market. For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy. 

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technology companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand their geographical presence. For instance, Bayer and Atara Biotherapeutics entered into a worldwide license agreement for the development of next-generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug types, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma. Recently in 2022, regulatory bodies expanded the approval of drugs for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as the global availability of the drug is the major factors which are the major factors aiding in the dominance of these factors.  

As per report findings, the Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028. The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy. Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support the growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments in clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

The report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market. The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives a competitive analysis of major market players that will give a competitive advantage to customers in their respective businesses. 

Report Highlights:

  • Research Methodology 
  • Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
  • Global & Regional Market Insight: Current & Market Forecast 2028
  • Approved CAR T Cell Therapies Sales Forecast Till 2028
  • Emerging In Vivo Induced CAR T Cell Therapies 
  • CAR T Cell Therapy Manufacturing Cost Analysis
  • CAR T Cell Therapy Approval & Reimbursement Scenario By Country
  • Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies 
  • Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
  • CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma


1. Research Methodology2. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
3.1 Structure of CAR-T Cell
3.2 1st Generation Chimeric Antigen Receptor
3.3 2nd & 3rd Generation CAR-T Cell
3.4 Principle of Chimeric Antigen Receptor Design
4. Approaches to Improve the Efficiency of CAR-T Cell Therapy5. CAR T Cell Therapy Manufacturing Cost Analysis
6. Emerging In-Vivo Induced CAR T Cell Therapies
6.1 Need of In-Vivo CAR T Cell Therapy
6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
6.3 Key Drug in Research & Development
7. Global CAR T Cell Therapy Market Outlook 2022 - 2028
7.1 Market Overview
7.2 Future Market Opportunity
8. Globally Approved CAR T Cell Therapies - Pricing, Dosage & Sales Analysis 2028
8.1 Tisagenlecleucel (Kymriah)
8.2 Axicabtagene Ciloleuce (Yescarta)
8.3 Brexucabtagene Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.5 Idecabtagene Vicleucel (Abecma)
8.6 Relmacabtagene autoleucel (Carteyva)
8.7 Ciltacabtagene autoleucel (Carvykti)
9. US CAR T Cell Therapy Market  Outlook
9.1 Approved & Key CAR T Cell Therapy Products in US
9.2 Market Overview
9.3 Current Reimbursement Scenario
10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved & Key CAR T Cell Therapy Products in Europe
10.2 UK
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current Reimbursement Scenario
11. China CAR T Cell Therapy Market Outlook
11.1 Approved & Key CAR T Cell Therapy Products in China
11.2 Current Market Size & Forecast
12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved & Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current Reimbursement Scenario
13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved & Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity
14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved & Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current Reimbursement Scenario
15. Taiwan CAR T Cell Therapy Market Outlook
16. Global CAR T Cells Clinical Pipeline Overview
16.1 By Company
16.2 By County
16.3 By Indication
16.4 By Phase
17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-III
17.8 Registered
18. Marketed CAR T Cell Therapy Clinical insight
18.1 Breyanzi
18.2 CARVYKTI
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
18.6 Tecartus
19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable Parameters
19.2 Market Challenges
20. Competitive Landscape
20.1 Autolus
20.2 Bellicum
20.3 Bluebird
20.4 Celgene
20.5 Cellectis
20.6 Celyad
20.7 Eureka Therapeutics
20.8 Fortress Biotech
20.9 Immune Therapeutics
20.10 Juno Therapeutics
20.11 Kite Pharma
20.12 Novartis
20.13 Sorrento therapeutics
20.14 TILT Biotherapeutics
20.15 Ziopharm
List of Figures
Figure 2-1: Historical Development of CAR-T Cell Therapy
Figure 3-1: Structure of Chimeric Antigen Receptor
Figure 3-2: First Generation Chimeric Antigen Receptor
Figure 3-3: Second Generation Chimeric Antigen Receptor
Figure 3-4: Third Generation Chimeric Antigen Receptor
Figure 3-5: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-6: Signalling Mechanism of Chimeric Antigen Receptor T-Cell
Figure 4-1: Strategies to Improve CAR T Cell Therapy
Figure 5-1: Flowchart for Manufacturing CAR T Cells
Figure 5-2: CAR T Cell - Annual Fixed Costs (US$)
Figure 5-3: CAR T Cell - Annual Fixed Costs (%)
Figure 5-4: CAR T Cell - Variable Cost Per Production (US$)
Figure 5-5: CAR T Cell - Variable Cost Per Production (%)
Figure 7-1: Global - Cancer Incidences & Deaths (Million), 2020
Figure 7-2: Global - CAR T Cell Therapy Market by Product (US$ Million), 2021
Figure 7-3: Global - CAR T Cell Therapy Market by Product (%), 2021
Figure 7-4: Global - CAR T Cell Therapy Market by Product (US$ Million), 2020
Figure 7-5: Global - CAR T Cell Therapy Market by Product (%), 2020
Figure 7-6: Global - CAR T Cell Therapy Market by Region (%), 2021
Figure 7-7: Global - CAR T Cell Therapy Market Size (US$ Billion), 2022 - 2028
Figure 8-1: US - Kymriah FDA Approval by Indication
Figure 8-2: Europe - Kymriah EMA Approval by Indication
Figure 8-3: Kymriah - Approval & Patent Exclusivity Year by Region
Figure 8-4: UK - Per Unit Price of Kymriah Infusion Bag (GBP/US$), May’2022
Figure 8-5: Kymriah - Per Unit Price of Intravenous Suspension by Region (US$), May’2022
Figure 8-6: Global - Kymriah Annual Sales (US$ Million), 2019 - 2021
Figure 8-7: Global - Kymriah Quarterly Sales (US$ Million), 2021
Figure 8-8: Global - Kymriah Quarterly Sales (US$ Million), 2020
Figure 8-9: Global - Kymriah Sales Forecast Value (US$ Million), 2022 - 2028
Figure 8-10: US - Yescarta FDA Approval by Indication
Figure 8-11: Yescarta - Approval Year by Region
Figure 8-12: US - Yescarta FDA Approval & Patent Expiration Year
Figure 8-13: UK - Per Unit Price of Yescarta Infusion Bag (GBP/US$), May’2022
Figure 8-14: Yescarta - Per Unit Price of Intravenous Suspension by Region (US$), May’2022
Figure 8-15: Yescarta - Global Sales by Region (US$ Million), Q1’2022
Figure 8-16: Yescarta - Global Sales by Region (%), Q1’2022
Figure 8-17: Global - Yescarta Annual Sales (US$ Million), 2018 - 2021
Figure 8-18: US - Yescarta Annual Sales (US$ Million), 2018 - 2021
Figure 8-19: Yescarta - Global Sales by Region (US$ Million), 2021
Figure 8-20: Yescarta - Global Sales by Region (%), 2021
Figure 8-21: Global - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-22: US - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-23: Europe - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-24: Global - Yescarta Quarterly Sales (US$ Million), 2020
Figure 8-25: Global - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-26: US - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-27: Europe - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-28: US - Tecartus FDA Approval by Indication
Figure 8-29: UK - Per Unit Price of Tecartus Infusion Bag (GBP/US$), May’2022
Figure 8-30: Tecartus - Per Unit Price of Intravenous Suspension by Region (US$), May’2022
Figure 8-31: Tecartus - Global Sales by Region (US$ Million), Q1’2022
Figure 8-32: Tecartus - Global Sale by Region (%), Q1’2022
Figure 8-33: Global - Tecartus Annual Sales (US$ Million), 2020 & 2021
Figure 8-34: US - Tecartus Annual Sales (US$ Million), 2020 & 2021
Figure 8-35: Tecartus - Global Sales by Region (US$ Million), 2021
Figure 8-36: Tecartus - Global Sales by Region (%), 2021
Figure 8-37: Global - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-38: US - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-39: Europe - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-40: Global - Tecartus Sales Forecast (US$ Million), 2022 - 2028
Figure 8-41: US - Tecartus Sales Forecast (US$ Million), 2022 - 2028
Figure 8-42: Breyanzi - Approval Year by Region
Figure 8-43: Breyanzi - Global Sales by Region (US$ Million), Q1’2022
Figure 8-44: Breyanzi - Global Sales by Region (%),Q1’2022
Figure 8-45: Global - Breyanzi Quarterly Sales (US$ Million), Q2-Q4’2021
Figure 8-46: Global - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-47: US - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-48: Abecma - Approval Year by Region
Figure 8-49: Abecma - Global Sales by Region (US$ Million), Q1’2022
Figure 8-50: Abecma - Global Sales by Region (%),Q1’2022
Figure 8-51: Abecma - Global Sales by Region (US$ Million), 2021
Figure 8-52: Abecma - Global Sales by Region (%), 2021
Figure 8-53: Global - Abecma Quarterly Sales (US$ Million), Q2-Q4’2021
Figure 8-54: US - Abecma Quarterly Sales (US$ Million), Q2-Q4’2021
Figure 8-55: Global - Abecma Sales Forecast (US$ Million), 2022 - 2028
Figure 8-56: US - Abecma Sales Forecast (US$ Million), 2022 - 2028
Figure 8-57: China - Carteyva Sales Forecast (US$ Million), 2022 - 2028
Figure 8-58: Global - Carvykti Sales Forecast (US$ Million), 2022 - 2028
Figure 9-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-2: US vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 9-3: US vs. ROW - CAR T Cell Therapy Market Size (%), 2021
Figure 9-4: US - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 9-5: US - Cost of Drug & Total Cost of Treatment with CAR T Cell Therapy (US$), 2021
Figure 9-6: US - Cost of Single Infusion & Reimbursement Cost for Abecma & Breyanzi (US$)
Figure 9-7: US - Out of Pocket Cost & Reimbursement Cost for Abecma & Breyanzi (%)
Figure 10-1: UK - Cancer Incidences & Deaths, 2020 & 2025
Figure 10-2: UK vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 10-3: UK vs. ROE - CAR T Cell Therapy Market Size (%), 2021
Figure 10-4: UK - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 10-5: Germany - Cancer Incidences & Deaths, 2020 & 2025
Figure 10-6: Germany vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 10-7: Germany vs. ROE - CAR T Cell Therapy Market Size (%), 2021
Figure 10-8: Germany - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 10-9: Spain - Cancer Incidences & Deaths, 2020 & 2025
Figure 10-10: Spain vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 10-11: Spain vs. ROE - CAR T Cell Therapy Market Size (%), 2021
Figure 10-12: Spain - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 10-13: France - Cancer Incidences & Deaths, 2020 & 2025
Figure 10-14: France vs. ROE - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 10-15: France vs. ROE - CAR T Cell Therapy Market Size (%), 2021
Figure 10-16: France - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 10-17: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-18: Europe vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 10-19: Europe vs. ROW - CAR T Cell Therapy Market Size (%), 2021
Figure 10-20: Rest of Europe - CAR T Cell Therapy Market Size (US$ Million), 2022 -2028
Figure 10-21: UK - Average Cost of Reimbursement with Kymriah & Yescarta per QALY (Euro/US$)
Figure 11-1: China - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 11-2: China - CAR T Clinical Trials by Phase’2020
Figure 11-3: China - Top 5 Pharmaceutical Companies Supporting CAR T Clinical Trials’2021
Figure 11-4: China - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
Figure 12-1: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 12-2: Japan vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 12-3: Japan vs. ROW - CAR T Cell Therapy Market Size (%), 2021
Figure 12-4: Japan - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 12-5: Japan - Current Retail & Reimbursed Price for Kymriah (JPY/US$), 2021
Figure 13-1: South Korea - Cancer Incidences & Deaths, 2020 & 2025
Figure 13-2: South Korea - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
Figure 14-1: Australia - Cancer Incidences & Deaths, 2020 & 2025
Figure 14-2: Australia vs. ROW - CAR T Cell Therapy Market Size (US$ Million), 2021
Figure 14-3: Australia vs. ROW - CAR T Cell Therapy Market Size (%), 2021
Figure 14-4: Australia - CAR T Cell Therapy Market Size (US$ Million), 2022 - 2028
Figure 15-1: Taiwan - CAR T Cell Therapy Market Size (US$ Million), 2021 - 2028
Figure 16-1: Global - CAR T Cells Clinical Pipeline by Company, 2022 till 2028
Figure 16-2: Global - CAR T Cells Clinical Pipeline by Country, 2022 till 2028
Figure 16-3: Global - CAR T Cells Clinical Pipeline by Indication, 2022 till 2028
Figure 16-4: Global - CAR T Cells Clinical Pipeline by Phase, 2022 till 2028
Figure 19-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 19-2: Challenges to Market Growth of CAR T Cell Therapy
List of Tables
Table 3-1: Antigens that are targeted by Chimeric Antigen Receptor
Table 5-1: CAR T Cell - Per Production Cost (US$)
Table 6-1: Advantage of VivoVec Platform over Traditional Platform
Table 6-2: ENLIGHTen - Phase I Trial Initiation & Completion Year
Table 9-1: US - FDA Approved CAR T Cell Therapy Products
Table 10-1: Europe - Approved CAR T Cell Therapy Products
Table 12-1: Japan - MHLW Approved CAR T Cell Therapy Products
Table 14-1: Australia -Approved CAR T Cell Therapy Products
Table 20-1: Clinical Pipelines of Products
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Autolus
  • Bellicum
  • Bluebird
  • Celgene
  • Cellectis
  • Celyad
  • Eureka Therapeutics
  • Fortress Biotech
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • Novartis
  • Sorrento therapeutics
  • TILT Biotherapeutics
  • Ziopharm
Note: Product cover images may vary from those shown